Newsworthy
March 2022
Congratulations to Qing on receiving a Shaffer Grant from the Glaucoma Research Foundation.
February 2022
Congratulations to both Aakriti and Sally on being accepted into graduate programs in neuroscience and medical school respectively. They will start in August 2022. We know they will hit the ground running.
January 2022
Research highlighted after clinical trail
January 2022
Promising results published for clinical trial treating glaucoma with the nutrients vitamin B3 and puyruvate.
April 2021
Congratulations to Revathi on being awarded a Bright Focus Foundation grant to study developmental glaucoma.
January 2021
Glaucoma and Genetics Come Into Focus
December 2020
Dr. John received the Sanford and Susan Greenberg Visionary Prize to End Blindness 20/20
Please read more at the following links:
National Geographic (subscription required)
New metabolic treatment strategies for glaucoma
Paper published in Proceedings of the National Academy of Sciences (PNAS). We discover further metabolic disturbances that contribute to glaucoma vulnerability. We expand the treatment options by showing that both pyruvate or rapamycin are protective against glaucoma. This builds on our concept of metabolic and resilience boosting treatments.
December 2019
Simon John joins the Department of Ophthalmology at Columbia University
April 2018
May 2017
Preserving Metabolic Function in Glaucoma
Further work from the John lab demonstrating that metabolism supporting, Resilence-based treatments are effectice against glaucoma. We that treatment with vitamin B3 enhances the effects of gene-based therapeutic interventions and protects from all assessed measures of glaucoma.
April 2017
Providing a Clearer View On Glaucoma Processes
Paper published in Proceedings of the National Academy of Sciences (PNAS) suggests that immune changes occur very early following IOP elevation and prior to any detected retinal ganglion cell dysfunction. The research provides evidence that astrocytes protect retinal ganglion cells during periods of increased pressure in the eye via a pathway involving complement C3.
February 2017
A breakthrough paper demonstrating metabolic abnormalities in glaucoma. We show that NAD boosting treatments, including gene therapy, are potently protective in an inherited mouse model of glaucoma. This work led to the concept of Resilience-boosting treatments that enhance bioenergetic and other cellular resources to prevent glaucoma.